None

Toripalimab (Toripalimab) is a PD-1 inhibitor used to treat advanced nasopharyngeal carcinoma (NPC) . Toripalimab is a next-generation programmed death receptor -1 (PD-1) monoclonal antibody that blocks PD-L1 and PD-L2, thereby activating the immune system and killing tumors. Toripalimab works by blocking the PD-1 receptor on tumor cells, so the immune system is more able to attack and kill the tumor cells.

Toripalimab is approved for use as first treatment, along with gemcitabine and cisplatin, when nasopharyngeal cancer has spread to other parts of the body (metastatic) or has recurred in nearby tissues (locally advanced). If the patient has received platinum-containing chemotherapy, but it is not effective or no longer effective, and the nasopharyngeal cancer has recurred, cannot be removed by surgery or has spread (metastatically), toripalimab can also be used for treatment. Toripalimab is also used to treat unresectable or metastatic melanoma that has not responded to prior systemic therapy. Toripalimab is also indicated as a second-line treatment for adults with locally advanced or metastatic urothelial carcinoma (UC).

When toripalimab was used as monotherapy, the most common side effects were fatigue, hypothyroidism, and musculoskeletal pain, which occurred in 20% or more of patients. When used in combination with cisplatin and gemcitabine, the most common side effects, which affect 20% or more of patients, are nausea, vomiting, decreased appetite, constipation, low thyroid levels, rash, fever, diarrhea, peripheral neuropathy, cough, muscle and joint pain, upper respiratory tract infection, sleep disturbance, dizziness, and malaise.